Clinical Trial Update: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH [Phase 2]

View source ↗

Summary

Phase 2 randomized trial assessing safety and efficacy of EDP-305 in non-alcoholic steatohepatitis (NASH) has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis

Drugs mentioned

• EDP-305

Snippet

Sponsor: Enanta Pharmaceuticals, Inc | Conditions: Non-Alcoholic Steatohepatitis | Phase 2 | Status: TERMINATED | Results posted: 2023-05-19